{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:21:49Z","timestamp":1788477709053,"version":"build-2803163510"},"reference-count":368,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2-SRA-2023\\u20131453-S-B"],"award-info":[{"award-number":["2-SRA-2023\\u20131453-S-B"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3-SRA-2024\\u20131562-S-B"],"award-info":[{"award-number":["3-SRA-2024\\u20131562-S-B"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK131070"],"award-info":[{"award-number":["R01 DK131070"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK127778"],"award-info":[{"award-number":["R01 DK127778"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK121929"],"award-info":[{"award-number":["R01 DK121929"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UG3 DK142184"],"award-info":[{"award-number":["UG3 DK142184"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK141150"],"award-info":[{"award-number":["R01 DK141150"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK133881"],"award-info":[{"award-number":["R01 DK133881"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015690","name":"South Carolina Clinical and Translational Research Institute, Medical University of South Carolina","doi-asserted-by":"publisher","award":["1TL1 TR001451\\u201301"],"award-info":[{"award-number":["1TL1 TR001451\\u201301"]}],"id":[{"id":"10.13039\/100015690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019970","name":"Diabetes Research Connection","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M and Harry B Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["AW00013368"],"award-info":[{"award-number":["AW00013368"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.smim.2025.101983","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:39:53Z","timestamp":1756402793000},"page":"101983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Autoimmune diabetes and targets for immunomodulation"],"prefix":"10.1016","volume":"79","author":[{"given":"Camillo","family":"Bechi Genzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyla","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bonami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raniero","family":"Chimienti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo M.R.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-8155","authenticated-orcid":false,"given":"Remi J.","family":"Creusot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41577-023-00985-4","article-title":"The immunology of type 1 diabetes","volume":"24","author":"Herold","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib2","series-title":"Seminars in immunopathology","first-page":"81","article-title":"Genetic overlap between type 1 diabetes and other autoimmune diseases","author":"M\u00e1rquez","year":"2022"},{"key":"10.1016\/j.smim.2025.101983_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886736","article-title":"Functional impact of risk gene variants on the autoimmune responses in type 1 diabetes","volume":"13","author":"Gootjes","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib4","article-title":"Genetics of type 1 diabetes","author":"Redondo","year":"2023","journal-title":"Diabetes Am. [Internet]"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002552","article-title":"The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines","volume":"8","author":"Eizirik","year":"2012","journal-title":"PLoS Genet."},{"issue":"18","key":"10.1016\/j.smim.2025.101983_bib6","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.15252\/embj.201696273","article-title":"The innate immune receptor MDA 5 limits rotavirus infection but promotes cell death and pancreatic inflammation","volume":"36","author":"Dou","year":"2017","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003532","article-title":"GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein bim","volume":"9","author":"Nogueira","year":"2013","journal-title":"PLoS Genet."},{"issue":"10035","key":"10.1016\/j.smim.2025.101983_bib8","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","article-title":"Environmental risk factors for type 1 diabetes","volume":"387","author":"Rewers","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2025.101983_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fendo.2020.00078","article-title":"The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis","volume":"11","author":"Dedrick","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.smim.2025.101983_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100003","article-title":"Immunodietica: a data-driven approach to investigate interactions between diet and autoimmune disorders","volume":"1","author":"Gershteyn","year":"2019","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.smim.2025.101983_bib11","doi-asserted-by":"crossref","first-page":"1326711","DOI":"10.3389\/fimmu.2023.1326711","article-title":"Immunological and virological triggers of type 1 diabetes: insights and implications","volume":"14","author":"Lemos","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-015-0656-8","article-title":"Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression","volume":"15","author":"Looney","year":"2015","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.smim.2025.101983_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fimmu.2015.00100","article-title":"Vitamin d actions on CD4+ t cells in autoimmune disease","volume":"6","author":"Hayes","year":"2015","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ni.3713","article-title":"Gut microbial metabolites limit the frequency of autoimmune t cells and protect against type 1 diabetes","volume":"18","author":"Marino","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib15","doi-asserted-by":"crossref","first-page":"1270488","DOI":"10.3389\/fimmu.2023.1270488","article-title":"Important denominator between autoimmune comorbidities: a review of class II HLA, autoimmune disease, and the gut","volume":"14","author":"Berryman","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2015.05.002","article-title":"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM)","volume":"14","author":"Kakleas","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib17","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1210\/jc.2016-2478","article-title":"T.D.E.C. Network, autoimmune diseases in children and adults with type 1 diabetes from the T1D exchange clinic registry","volume":"101","author":"Hughes","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2337\/dc19-2429","article-title":"Every fifth individual with type 1 diabetes suffers from an additional autoimmune disease: a Finnish nationwide study","volume":"43","author":"M\u00e4kimattila","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4239\/wjd.v11.i11.527","article-title":"Type 1 diabetes and associated autoimmune diseases","volume":"11","author":"Frommer","year":"2020","journal-title":"World J. Diabetes"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/jpm13030422","article-title":"Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized Medicine","volume":"13","author":"Popoviciu","year":"2023","journal-title":"J. Pers. Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00125-024-06086-8","article-title":"Autoimmune comorbidity in type 1 diabetes and its association with metabolic control and mortality risk in young people: a population-based study","volume":"67","author":"Samuelsson","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib22","article-title":"Type 1 diabetes and other autoimmune disorders in children","volume":"2024","author":"Grasso","year":"2024","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874769","article-title":"The NOD mouse beyond autoimmune diabetes","volume":"13","author":"Aubin","year":"2022","journal-title":"Front. Immunol."},{"issue":"13-14","key":"10.1016\/j.smim.2025.101983_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.drudis.2010.05.013","article-title":"Interference with islet-specific homing of autoreactive t cells: an emerging therapeutic strategy for type 1 diabetes","volume":"15","author":"Savinov","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/cei\/uxad083","article-title":"Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes","volume":"214","author":"Christen","year":"2023","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib26","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.4049\/jimmunol.178.9.5643","article-title":"Tertiary lymphoid structures in the pancreas promote selection of b lymphocytes in autoimmune diabetes","volume":"178","author":"Kendall","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib27","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00125-021-05453-z","article-title":"Identification and characterisation of tertiary lymphoid organs in human type 1 diabetes","volume":"64","author":"Korpos","year":"2021","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2337\/db09-1129","article-title":"Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs","volume":"59","author":"Penaranda","year":"2010","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4049\/jimmunol.0903710","article-title":"CXCL13 blockade disrupts b lymphocyte organization in tertiary lymphoid structures without altering b cell receptor bias or preventing diabetes in nonobese diabetic mice","volume":"185","author":"Henry","year":"2010","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib30","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.2337\/db19-0239","article-title":"CCL21 expression in \u03b2-cells induces antigen-expressing stromal cell networks in the pancreas and prevents autoimmune diabetes in mice","volume":"68","author":"Gonzalez Badillo","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13578-023-01110-7","article-title":"Pancreatic draining lymph nodes (PLNs) serve as a pathogenic hub contributing to the development of type 1 diabetes","volume":"13","author":"Sun","year":"2023","journal-title":"Cell Biosci."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib32","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1016\/j.celrep.2016.08.033","article-title":"Reprogramming the local lymph node microenvironment promotes tolerance that is systemic and antigen specific","volume":"16","author":"Tostanoski","year":"2016","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMc1616343","article-title":"Intralymphatic injection of autoantigen in type 1 diabetes","volume":"376","author":"Ludvigsson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.101983_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564921","article-title":"Glutamic acid decarboxylase injection into lymph nodes: beta cell function and immune responses in recent onset type 1 diabetes patients","volume":"11","author":"Casas","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.797172","article-title":"Intralymphatic GAD-alum injection modulates b cell response and induces follicular helper t cells and PD-1+ CD8+ t cells in patients with recent-onset type 1 diabetes","volume":"12","author":"Barcenilla","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib36","doi-asserted-by":"crossref","first-page":"1112570","DOI":"10.3389\/fimmu.2023.1112570","article-title":"Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype","volume":"14","author":"Puente-Marin","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib37","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.immuni.2024.07.024","article-title":"CD4+ t cells reactive to a hybrid peptide from insulin-chromogranin a adopt a distinct effector fate and are pathogenic in autoimmune diabetes","volume":"57","author":"Mitchell","year":"2024","journal-title":"Immunity"},{"issue":"7895","key":"10.1016\/j.smim.2025.101983_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","article-title":"An autoimmune stem-like CD8 t cell population drives type 1 diabetes","volume":"602","author":"Gearty","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101983_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2154098","article-title":"Epitope-based precision immunotherapy of type 1 diabetes","author":"Firdessa Fite","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00281-022-00942-8","article-title":"Harnessing the liver to induce antigen-specific immune tolerance","volume":"44","author":"Gottwick","year":"2022","journal-title":"Semin Immunopathol."},{"key":"10.1016\/j.smim.2025.101983_bib41","series-title":"Mucosal Vaccines","first-page":"21","article-title":"Anatomical uniqueness of the mucosal immune system (GALT, NALT, iBALT) for the induction and regulation of mucosal immunity and tolerance","author":"Silva-Sanchez","year":"2020"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/nano14010067","article-title":"Liver-Targeting nanoplatforms for the induction of immune tolerance","volume":"14","author":"Kusumoputro","year":"2023","journal-title":"Nanomaterials"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib43","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","article-title":"An update on oral drug delivery via intestinal lymphatic transport","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201701079","article-title":"Oral nonviral gene delivery for chronic protein replacement therapy","volume":"5","author":"Lin","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.smim.2025.101983_bib45","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fimmu.2020.01103","article-title":"Intestinal delivery of proinsulin and IL-10 via lactococcus lactis combined with low-dose anti-CD3 restores tolerance outside the window of acute type 1 diabetes diagnosis","volume":"11","author":"Cook","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-023-06014-2","article-title":"A first-in-human, open-label phase 1b and a randomised, double-blind phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab","volume":"67","author":"Mathieu","year":"2024","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/vaccines12030276","article-title":"Mechanism of action of oral Salmonella-Based vaccine to prevent and reverse type 1 diabetes in NOD mice","volume":"12","author":"Cobb","year":"2024","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303863","article-title":"Reversal of diabetes by an oral Salmonella-based vaccine in acute and progressive diabetes in NOD mice","volume":"19","author":"Cobb","year":"2024","journal-title":"Plos One"},{"issue":"24","key":"10.1016\/j.smim.2025.101983_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162720","article-title":"Pharmacological conversion of gut epithelial cells into insulin-producing cells lowers glycemia in diabetic animals","volume":"132","author":"Du","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.101983_bib50","doi-asserted-by":"crossref","first-page":"1339714","DOI":"10.3389\/fimmu.2024.1339714","article-title":"Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis","volume":"15","author":"Shirafkan","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib51","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1182\/blood-2006-03-010900","article-title":"Induction of antigen-specific tolerance by intrathymic injection of lentiviral vectors","volume":"108","author":"Marodon","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.smim.2025.101983_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtm.2022.04.017","article-title":"Editing t cell repertoire by thymic epithelial cell-directed gene transfer abrogates risk of type 1 diabetes development","volume":"25","author":"Russo","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib53","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/db21-1069","article-title":"Antibody-mediated targeting of a hybrid insulin peptide toward neonatal thymic langerin-positive cells enhances T-cell central tolerance and delays autoimmune diabetes","volume":"71","author":"Lin","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676236","article-title":"Age-related changes in thymic central tolerance","volume":"12","author":"Srinivasan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib55","article-title":"Human beta cell regenerative drug therapy for diabetes: past achievements and future challenges","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib56","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/cells12111472","article-title":"Emerging anti-diabetic drugs for Beta-cell protection in type 1 diabetes","volume":"12","author":"Ajmal","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.smim.2025.101983_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2024.03.006","article-title":"Harnessing beta cell regeneration biology for diabetes therapy","author":"Bourgeois","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.smim.2025.101983_bib58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2018.08.011","article-title":"Harnessing CXCL12 signaling to protect and preserve functional \u03b2-cell mass and for cell replacement in type 1 diabetes","volume":"193","author":"Alagpulinsa","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.smim.2025.101983_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1427723","article-title":"Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival?","volume":"15","author":"Webster","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cmet.2017.01.005","article-title":"\u03b2 cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice","volume":"25","author":"Rui","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.smim.2025.101983_bib61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor\u2013induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"issue":"7213","key":"10.1016\/j.smim.2025.101983_bib62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nature07314","article-title":"In vivo reprogramming of adult pancreatic exocrine cells to \u03b2-cells","volume":"455","author":"Zhou","year":"2008","journal-title":"nature"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib63","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng.2215","article-title":"Generation of functional insulin-producing cells in the gut by Foxo1 ablation","volume":"44","author":"Talchai","year":"2012","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.smim.2025.101983_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101365","article-title":"An accomplice more than a mere victim: the impact of \u03b2-cell ER stress on type 1 diabetes pathogenesis","volume":"54","author":"Sahin","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MED.0000000000000548","article-title":"The role of beta-cell dysfunction in early type 1 diabetes","volume":"27","author":"Sims","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib67","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.cmet.2023.10.014","article-title":"Stress-induced \u03b2 cell early senescence confers protection against type 1 diabetes","volume":"35","author":"Lee","year":"2023","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib68","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cmet.2020.03.002","article-title":"Beta cell dedifferentiation induced by IRE1\u03b1 deletion prevents type 1 diabetes","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib69","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MED.0000000000000391","article-title":"Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP","volume":"25","author":"Thielen","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib70","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.cmet.2019.01.021","article-title":"Targeted elimination of senescent beta cells prevents type 1 diabetes","volume":"29","author":"Thompson","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.smim.2025.101983_bib71","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00726-013-1560-7","article-title":"Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy","volume":"46","author":"Tersey","year":"2014","journal-title":"Amino Acids"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib72","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s00125-024-06106-7","article-title":"Interferons are key cytokines acting on pancreatic islets in type 1 diabetes","volume":"67","author":"Coomans de Brach\u00e8ne","year":"2024","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib73","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2337\/db12-0112","article-title":"Diabetogenic T-cell clones recognize an altered peptide of chromogranin a","volume":"61","author":"Delong","year":"2012","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cei.12775","article-title":"Human islets and dendritic cells generate post-translationally modified islet autoantigens","volume":"185","author":"McLaughlin","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib75","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2337\/db18-0295","article-title":"Inflammation-induced citrullinated glucose-regulated protein 78 elicits immune responses in human type 1 diabetes","volume":"67","author":"Buitinga","year":"2018","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib76","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/db21-0989","article-title":"Carbonyl posttranslational modification associated with early-onset type 1 diabetes autoimmunity","volume":"71","author":"Yang","year":"2022","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib77","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2337\/db23-0588","article-title":"CD4+ t cells from individuals with type 1 diabetes respond to a novel class of deamidated peptides formed in pancreatic islets","volume":"73","author":"Callebaut","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101809","article-title":"The beta cell-immune cell interface in type 1 diabetes (T1D)","author":"James","year":"2023","journal-title":"Mol. Metab."},{"key":"10.1016\/j.smim.2025.101983_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.624590","article-title":"The role of \u03b2 cell stress and neo-epitopes in the immunopathology of type 1 diabetes","volume":"11","author":"Piganelli","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105264","article-title":"Hybrid insulin peptide isomers spontaneously form in pancreatic beta-cells from an aspartic anhydride intermediate","volume":"299","author":"Crawford","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.smim.2025.101983_bib81","doi-asserted-by":"crossref","first-page":"1348131","DOI":"10.3389\/fimmu.2024.1348131","article-title":"Mapping of a hybrid insulin peptide in the inflamed islet \u03b2-cells from NOD mice","volume":"15","author":"Wenzlau","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667870","article-title":"Identifying new hybrid insulin peptides (HIPs) in type 1 diabetes","volume":"12","author":"Mannering","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib83","first-page":"1","article-title":"The insulin secretory granule is a hotspot for autoantigen formation in type 1 diabetes","author":"Groegler","year":"2024","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107612","article-title":"A structural basis of t cell cross-reactivity to native and spliced self-antigens presented by HLA-DQ8","volume":"300","author":"Tran","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib85","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm.4289","article-title":"Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes","volume":"23","author":"Kracht","year":"2017","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib86","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/db11-0955","article-title":"Preventing \u03b2-cell loss and diabetes with calcium channel blockers","volume":"61","author":"Xu","year":"2012","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib87","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2023.2064","article-title":"Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial","volume":"329","author":"Forlenza","year":"2023","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib88","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","article-title":"Verapamil and beta cell function in adults with recent-onset type 1 diabetes","volume":"24","author":"Ovalle","year":"2018","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.smim.2025.101983_bib89","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib90","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"23","key":"10.1016\/j.smim.2025.101983_bib91","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib92","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves \u03b2-cell function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib93","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00007890-199004000-00009","article-title":"In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids","volume":"49","author":"Chatenoud","year":"1990","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib95","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","article-title":"CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice","volume":"158","author":"Chatenoud","year":"1997","journal-title":"Journal immunology (Baltimore Md. 1950)"},{"issue":"22","key":"10.1016\/j.smim.2025.101983_bib96","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib97","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI16090","article-title":"Activation of human t cells by FcR nonbinding anti-CD3 mab, hOKT3\u03b31 (Ala-Ala)","volume":"111","author":"Herold","year":"2003","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib98","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3\u03b31 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"issue":"9790","key":"10.1016\/j.smim.2025.101983_bib99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib100","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"583","key":"10.1016\/j.smim.2025.101983_bib102","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib103","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/clinem\/dgad328","article-title":"Screening and prevention of type 1 diabetes: where are we?","volume":"108","author":"Simmons","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib104","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes care"},{"issue":"9789","key":"10.1016\/j.smim.2025.101983_bib105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib106","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib107","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"21","key":"10.1016\/j.smim.2025.101983_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167881","article-title":"Islet-autoreactive CD4+ t cells are linked with response to alefacept in type 1 diabetes","volume":"8","author":"Balmas","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.smim.2025.101983_bib109","doi-asserted-by":"crossref","first-page":"1264327","DOI":"10.3389\/fimmu.2023.1264327","article-title":"Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors","volume":"14","author":"Roy","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib110","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/eji.200839177","article-title":"Attenuation of Th1 response through galectin-9 and T-cell ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice","volume":"39","author":"Chou","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib111","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1210\/en.2011-1579","article-title":"Galectin-9 and t cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes","volume":"153","author":"Kanzaki","year":"2012","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib112","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4049\/jimmunol.1900823","article-title":"A LAG-3\u2013specific agonist antibody for the treatment of t cell\u2013induced autoimmune diseases","volume":"204","author":"Angin","year":"2020","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib113","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s42003-023-04874-3","article-title":"Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting tfh and tph cells and enhancing treg cells","volume":"6","author":"Kojima","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.smim.2025.101983_bib114","first-page":"qiae116","article-title":"TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration","author":"Peters","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.smim.2025.101983_bib115","doi-asserted-by":"crossref","first-page":"1090842","DOI":"10.3389\/fendo.2022.1090842","article-title":"Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes","volume":"13","author":"Ding","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib116","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13543784.2024.2326036","article-title":"Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes","volume":"33","author":"Maddaloni","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib117","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2337\/db12-1175","article-title":"Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes","volume":"62","author":"Hu","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib118","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2337\/db15-0492","article-title":"A preclinical consortium approach for assessing the efficacy of combined anti-CD3 plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD mice","volume":"65","author":"Gill","year":"2016","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib119","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.2337\/db15-0479","article-title":"Anti-CD3\/anti-CXCL10 antibody combination therapy induces a persistent remission of type 1 diabetes in two mouse models","volume":"64","author":"Lasch","year":"2015","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib120","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2337\/db23-0178","article-title":"Reversal of experimental autoimmune diabetes with an sCD39\/anti-CD3 treatment","volume":"72","author":"Fotino","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib121","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fimmu.2019.00320","article-title":"Reversal of new onset type 1 diabetes by oral salmonella-based combination therapy and mediated by regulatory T-cells in NOD mice","volume":"10","author":"Mbongue","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib122","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI27191","article-title":"Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing tregs","volume":"116","author":"Bresson","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib123","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2337\/db08-0138","article-title":"Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+ CD25+ FOXP3+ regulatory T-cells","volume":"57","author":"Monti","year":"2008","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib124","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/acsbiomaterials.9b00332","article-title":"Dual-sized microparticle system for generating suppressive dendritic cells prevents and reverses type 1 diabetes in the nonobese diabetic mouse model","volume":"5","author":"Lewis","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.smim.2025.101983_bib125","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1007\/s13346-021-01075-5","article-title":"Biomaterial-enabled induction of pancreatic-specific regulatory t cells through distinct signal transduction pathways","volume":"11","author":"Carey","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.smim.2025.101983_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683091","article-title":"Means, motive, and opportunity: do non-islet-reactive infiltrating t cells contribute to autoimmunity in type 1 diabetes?","volume":"12","author":"Rodriguez-Calvo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib127","doi-asserted-by":"crossref","first-page":"1462384","DOI":"10.3389\/fimmu.2024.1462384","article-title":"The role of islet autoantigen-specific t cells in the onset and treatment of type 1 diabetes mellitus","volume":"15","author":"Yue","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib128","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2337\/dbi19-0022","article-title":"T-cell epitopes and neo-epitopes in type 1 diabetes: a comprehensive update and reappraisal","volume":"69","author":"James","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib129","first-page":"1","article-title":"T cell and autoantibody recognition of nucleus-associated islet autoantigens in individuals with type 1 diabetes","author":"Guyer","year":"2025","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10991","article-title":"Type 1 diabetes vaccine candidates promote human Foxp3+ treg induction in humanized mice","volume":"7","author":"Serr","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib131","doi-asserted-by":"crossref","first-page":"2154098","DOI":"10.1080\/21645515.2022.2154098","article-title":"Epitope-based precision immunotherapy of type 1 diabetes","volume":"19","author":"Fite","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100827","article-title":"Noncontiguous t cell epitopes in autoimmune diabetes: from mice to men and back again","volume":"297","author":"Amdare","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"7591","key":"10.1016\/j.smim.2025.101983_bib133","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101983_bib134","doi-asserted-by":"crossref","first-page":"1177722","DOI":"10.3389\/fimmu.2023.1177722","article-title":"Transcriptional re-programming of insulin B-chain epitope-specific T-follicular helper cells into anti-diabetogenic T-regulatory type-1 cells","volume":"14","author":"Sol\u00e9","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98716-z","article-title":"Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific t cells","volume":"11","author":"Seidel","year":"2021","journal-title":"Sci. Rep."},{"issue":"23","key":"10.1016\/j.smim.2025.101983_bib136","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141051","article-title":"T cell receptor\u2013targeted immunotherapeutics drive selective in vivo HIV-and CMV-specific t cell expansion in humanized mice","volume":"131","author":"Li","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.101983_bib137","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fimmu.2020.00472","article-title":"The emerging jamboree of transformative therapies for autoimmune diseases","volume":"11","author":"Carballido","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib138","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/imcb.12439","article-title":"A century later, still fighting back: antigen-specific immunotherapies for type 1 diabetes","volume":"99","author":"Rodriguez-Fernandez","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.smim.2025.101983_bib139","first-page":"a041598","article-title":"Autoantigen-Specific immunotherapies for the prevention and treatment of type 1 diabetes","author":"Peakman","year":"2024","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","article-title":"Therapeutic induction of antigen-specific immune tolerance","volume":"24","author":"Kenison","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061776","volume":"12","author":"Ludvigsson","year":"2022","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib142","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1210\/clinem\/dgac343","article-title":"Intralymphatic GAD-alum (Diamyd\u00ae) improves glycemic control in type 1 diabetes with HLA DR3-DQ2, the","volume":"107","author":"Nowak","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib143","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ng2068","article-title":"Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes","volume":"39","author":"Todd","year":"2007","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib144","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ahg.12406","article-title":"Association of variants in PTPN22, CTLA-4, IL2-RA, and INS genes with type 1 diabetes in Emiratis","volume":"85","author":"Sharma","year":"2021","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.smim.2025.101983_bib145","doi-asserted-by":"crossref","first-page":"1075813","DOI":"10.3389\/fimmu.2022.1075813","article-title":"The emerging role of regulatory cell-based therapy in autoimmune disease","volume":"13","author":"Ghobadinezhad","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib146","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory t cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib147","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","article-title":"An essential role for scurfin in CD4+ CD25+ t regulatory cells","volume":"4","author":"Khattri","year":"2003","journal-title":"Nat. Immunol."},{"issue":"5609","key":"10.1016\/j.smim.2025.101983_bib148","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory t cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib149","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+ CD25+ regulatory t cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib151","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmg.39.8.537","article-title":"A. Filipovich, clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, x linked (IPEX) syndrome","volume":"39","author":"Wildin","year":"2002","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib152","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.4049\/jimmunol.1100272","article-title":"Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+ CD25+ regulatory t cell function","volume":"188","author":"Garg","year":"2012","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib153","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db15-0516","article-title":"Natural variation in interleukin-2 sensitivity influences regulatory T-cell frequency and function in individuals with long-standing type 1 diabetes","volume":"64","author":"Yang","year":"2015","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib154","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro\u2013expanded antigen-specific regulatory t cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J. Exp. Med."},{"issue":"315","key":"10.1016\/j.smim.2025.101983_bib155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory t cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib156","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+ CD25highCD127\u2212 regulatory t cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes care"},{"issue":"746","key":"10.1016\/j.smim.2025.101983_bib157","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn2404","article-title":"A phase 2 randomized trial with autologous polyclonal expanded regulatory t cells in children with new-onset type 1 diabetes","volume":"16","author":"Bender","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101983_bib158","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","article-title":"Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I\/II randomised, double-blind, placebo-controlled, dose-finding study","volume":"63","author":"Rosenzwajg","year":"2020","journal-title":"Diabetologia"},{"issue":"18","key":"10.1016\/j.smim.2025.101983_bib159","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"issue":"6379","key":"10.1016\/j.smim.2025.101983_bib160","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered t cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib161","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139991","article-title":"Selective expansion of regulatory t cells using an orthogonal IL-2\/IL-2 receptor system facilitates transplantation tolerance","volume":"131","author":"Hirai","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib162","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/dom.14723","article-title":"Combined therapy with CD4+ CD25highCD127\u2212 t regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: randomized phase I\/II trial","volume":"24","author":"Zieli\u0144ski","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.smim.2025.101983_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.873560","article-title":"Human CD4+ CD25+ CD226-tregs demonstrate increased purity, lineage stability, and suppressive capacity versus CD4+ CD25+ CD127lo\/-tregs for adoptive cell therapy","volume":"13","author":"Brown","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib164","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2337\/db23-0307","article-title":"Treg-Specific CD226 deletion reduces diabetes incidence in NOD mice by improving regulatory T-Cell stability","volume":"72","author":"Thirawatananond","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib165","first-page":"1","article-title":"Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory t cells and diminishing effector t cell function","author":"Brown","year":"2024","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib166","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.4049\/jimmunol.1102661","article-title":"The role of naive t cell precursor frequency and recruitment in dictating immune response magnitude","volume":"188","author":"Jenkins","year":"2012","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib167","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350506","article-title":"Frequency of natural regulatory t cells specific for factor VIII in the peripheral blood of healthy donors","volume":"54","author":"Menier","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib168","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory t cells expressing de novo autoreactive T-cell receptors in type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front. Immunol."},{"issue":"665","key":"10.1016\/j.smim.2025.101983_bib169","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"issue":"18","key":"10.1016\/j.smim.2025.101983_bib171","article-title":"Tregs with an MHC class II peptide\u2013specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.101983_bib172","doi-asserted-by":"crossref","first-page":"1207108","DOI":"10.3389\/fimmu.2023.1207108","article-title":"Regulatory t cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes","volume":"14","author":"Obarorakpor","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib173","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/dc21-2688","article-title":"Long-term outcomes with islet-alone and islet-after-kidney transplantation for type 1 diabetes in the clinical islet transplantation consortium: the CIT-08 study","volume":"45","author":"Rickels","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib174","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0198-8859(99)00155-X","article-title":"Frequencies of HLA-A2 alleles in five US population groups: predominance of A\u2217 02011 and identification of HLA-A\u2217 0231","volume":"61","author":"Ellis","year":"2000","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory t cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114994","article-title":"Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory t cells","volume":"43","author":"Barra","year":"2024","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib177","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.stem.2024.05.004","article-title":"Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model","volume":"31","author":"Yano","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.smim.2025.101983_bib178","doi-asserted-by":"crossref","first-page":"1463971","DOI":"10.3389\/fimmu.2024.1463971","article-title":"Regulatory CD4+ t cells redirected against pathogenic CD8+ t cells protect NOD mice from development of autoimmune diabetes","volume":"15","author":"Kakabadse","year":"2024","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.smim.2025.101983_bib179","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1182\/blood-2006-06-027409","article-title":"Only the CD45RA+ subpopulation of CD4+ CD25high t cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion","volume":"108","author":"Hoffmann","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.coi.2009.05.007","article-title":"Plasticity of CD4+ FoxP3+ t cells","volume":"21","author":"Zhou","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib181","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","article-title":"The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory t cell identity after activation","volume":"42","author":"DuPage","year":"2015","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib182","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4049\/jimmunol.2300216","article-title":"Regulatory t cell insufficiency in autoimmune diabetes is driven by selective loss of neuropilin-1 on intraislet regulatory t cells","volume":"213","author":"Grebinoski","year":"2024","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib183","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib184","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126194","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory t cell function","volume":"4","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"issue":"557","key":"10.1016\/j.smim.2025.101983_bib185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory t cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101385","article-title":"High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory t cells","volume":"32","author":"Cochrane","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.smim.2025.101983_bib187","doi-asserted-by":"crossref","first-page":"1415102","DOI":"10.3389\/fimmu.2024.1415102","article-title":"CD39 delineates chimeric antigen receptor regulatory t cell subsets with distinct cytotoxic & regulatory functions against human islets","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103057","article-title":"Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","volume":"138","author":"Henschel","year":"2023","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib189","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/eji.202048934","article-title":"Chimeric antigen receptor-modified human regulatory t cells that constitutively express IL-10 maintain their phenotype and are potently suppressive","volume":"51","author":"Mohseni","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib190","article-title":"The role of b lymphocytes in type 1 diabetes","author":"Smith","year":"2024","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib191","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.184.5.2049","article-title":"B lymphocytes are essential for the initiation of t cell-mediated autoimmune diabetes: analysis of a new ''speed congenic'' stock of NOD.Ig mu(null) mice","volume":"184","author":"Serreze","year":"1996","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib192","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4049\/jimmunol.163.2.743","article-title":"I-A-mediated antigen presentation by b lymphocytes is critical in overcoming a checkpoint in t cell tolerance to islet \u03b2 cells of nonobese diabetic mice","volume":"163","author":"Noorchashm","year":"1999","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib193","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.4049\/jimmunol.167.10.5535","article-title":"B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice","volume":"167","author":"Hulbert","year":"2001","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib194","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/1521-4141(200212)32:12<3657::AID-IMMU3657>3.0.CO;2-E","article-title":"The preferential ability of b lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors","volume":"32","author":"Silveira","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib195","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/db11-1746","article-title":"Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes","volume":"61","author":"Henry","year":"2012","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib196","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.4049\/jimmunol.1202104","article-title":"Tolerant anti-insulin b cells are effective APCs","volume":"190","author":"Kendall","year":"2013","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib197","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.161.8.3912","article-title":"B lymphocytes are critical antigen-presenting cells for the initiation of t cell-mediated autoimmune diabetes in nonobese diabetic mice","volume":"161","author":"Serreze","year":"1998","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.smim.2025.101983_bib198","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1073\/pnas.1502967112","article-title":"Regulatory vs. Inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects","volume":"112","author":"Nakayama","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib199","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221604","article-title":"Identification of an anergic BND cell\u2013derived activated b cell population (BND2) in young-onset type 1 diabetes patients","volume":"220","author":"Stensland","year":"2023","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4049\/immunohorizons.2300036","article-title":"Productive germinal center responses depend on the nature of stimuli received by Anti-Insulin b cells in type 1 Diabetes\u2013Prone mice","volume":"7","author":"McNitt","year":"2023","journal-title":"Immunohorizons"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib201","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20151869","article-title":"Class-switched anti-insulin antibodies originate from unconventional antigen presentation in multiple lymphoid sites","volume":"213","author":"Wan","year":"2016","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.smim.2025.101983_bib202","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585886","article-title":"Insulin-Reactive t cells convert diabetogenic Insulin-Reactive VH125 b cells into tolerogenic cells by reducing germinal center T:B cell interactions in NOD mice","volume":"11","author":"Pearson","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.746187","article-title":"Regulatory b cells: role in type 1 diabetes","volume":"12","author":"Boldison","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib204","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/db13-1639","article-title":"Interleukin-10+ regulatory b cells arise within antigen-experienced CD40+ b cells to maintain tolerance to islet autoantigens","volume":"64","author":"Kleffel","year":"2015","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4049\/jimmunol.1701717","article-title":"Anti-Insulin b cells are poised for antigen presentation in type 1 diabetes","volume":"201","author":"Felton","year":"2018","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib206","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"C. Rituximab consensus expert, updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib207","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib208","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1172\/JCI32405","article-title":"Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice","volume":"117","author":"Hu","year":"2007","journal-title":"J. Clin. Invest"},{"issue":"22","key":"10.1016\/j.smim.2025.101983_bib209","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"C.D.S.G. Type 1 diabetes TrialNet anti, rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib210","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early b cell tolerance checkpoints","volume":"126","author":"Chamberlain","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib211","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/db11-0674","article-title":"C.D.S.G. Type 1 diabetes TrialNet anti, rituximab selectively suppresses specific islet antibodies","volume":"60","author":"Yu","year":"2011","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib212","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib213","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","article-title":"G. Type 1 diabetes TrialNet study, effect of rituximab on human in vivo antibody immune responses","volume":"128","author":"Pescovitz","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib214","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific t cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib215","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.4049\/jimmunol.161.8.3919","article-title":"Positive and negative regulation of human t cell activation mediated by the CTLA-4\/CD28 ligand CD80","volume":"161","author":"Boulougouris","year":"1998","journal-title":"J. Immunol."},{"issue":"9789","key":"10.1016\/j.smim.2025.101983_bib216","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"1 diabetes TrialNet abatacept study, Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib217","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"G. Type 1 diabetes TrialNet study, abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, Double-Masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib218","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41590-020-0744-z","article-title":"Follicular helper t cell profiles predict response to costimulation blockade in type 1 diabetes","volume":"21","author":"Edner","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib219","first-page":"db230709","article-title":"Type 1 diabetes depends on CD4-driven expression of the transcriptional repressor, Bcl6","author":"McNitt","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib220","unstructured":"T.D. TrialNet, Rituximab-pvvr \/ Abatacept Newly Diagnosed Study (T1D RELAY). \u3008https:\/\/www.trialnet.org\/our-research\/newly-diagnosed-t1d\/t1d-relay\u3009. (Accessed 10\/15\/2024 2024)."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib221","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.040556697","article-title":"Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes","volume":"97","author":"Yu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib222","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","article-title":"Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention Trial--Type 1","volume":"28","author":"Skyler","year":"2005","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.smim.2025.101983_bib223","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","article-title":"Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial","volume":"318","author":"Krischer","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib224","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/biomedicines9010042","article-title":"B quiet: autoantigen-specific strategies to silence raucous b lymphocytes and halt cross-talk with t cells in type 1 diabetes","volume":"9","author":"Felton","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib225","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.4049\/jimmunol.166.5.3194","article-title":"Anergy and not clonal ignorance determines the fate of b cells that recognize a physiological autoantigen","volume":"166","author":"Rojas","year":"2001","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib226","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.4049\/jimmunol.1500438","article-title":"Targeting Anti-Insulin b cell receptors improves receptor editing in type 1 Diabetes-Prone mice","volume":"195","author":"Bonami","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib227","doi-asserted-by":"crossref","first-page":"1367514","DOI":"10.3389\/fimmu.2024.1367514","article-title":"An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific b cells and prevents murine autoimmune diabetes","volume":"15","author":"Alleva","year":"2024","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib228","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1021\/acs.molpharmaceut.8b01250","article-title":"Soluble antigen arrays for selective desensitization of Insulin-Reactive b cells","volume":"16","author":"Leon","year":"2019","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib229","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/db17-1564","article-title":"Altered function of antigen-presenting cells in type 1 diabetes: a challenge for antigen-specific immunotherapy?","volume":"67","author":"Creusot","year":"2018","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib230","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1172\/JCI97739","article-title":"Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes","volume":"128","author":"Ostrov","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.smim.2025.101983_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102543","article-title":"Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes","volume":"115","author":"Lombardi","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.smim.2025.101983_bib232","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaut.2013.08.009","article-title":"Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive t cell epitope","volume":"47","author":"Dahan","year":"2013","journal-title":"J. Autoimmun."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib233","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1323436111","article-title":"Monoclonal antibody blocking the recognition of an insulin peptide\u2013MHC complex modulates type 1 diabetes","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2025.101983_bib234","series-title":"A monoclonal antibody with broad specificity for the ligands of insulin B: 9-23 reactive t cells prevents spontaneous type 1 diabetes in mice, MAbs","first-page":"1836714","author":"Cepeda","year":"2020"},{"key":"10.1016\/j.smim.2025.101983_bib235","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bbrc.2020.11.019","article-title":"A TCR-like antibody against a proinsulin-containing fusion peptide ameliorates type 1 diabetes in NOD mice","volume":"534","author":"Matsumoto","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib236","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12916-023-02900-z","article-title":"First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes","volume":"21","author":"Van Rampelbergh","year":"2023","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib237","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/imm.13298","article-title":"Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis","volume":"162","author":"Carambia","year":"2021","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib238","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41551-023-01086-2","article-title":"Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses","volume":"7","author":"Tremain","year":"2023","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib239","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4049\/jimmunol.2200208","article-title":"Tolerogenic immune-modifying nanoparticles encapsulating multiple recombinant pancreatic \u03b2 cell proteins prevent onset and progression of type 1 diabetes in nonobese diabetic mice","volume":"209","author":"Podojil","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103125","article-title":"Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory t cells for protection against autoimmune disease","volume":"140","author":"Kishimoto","year":"2023","journal-title":"J. Autoimmun."},{"issue":"433","key":"10.1016\/j.smim.2025.101983_bib241","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad0612","article-title":"Tolerogenic nanoparticles inhibit t cell\u2013mediated autoimmunity through SOCS2","volume":"9","author":"Yeste","year":"2016","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib242","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801419","article-title":"Engineering immune tolerance with biomaterials","volume":"8","author":"Gammon","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.smim.2025.101983_bib243","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864403","article-title":"Nanoparticles for inducing antigen-specific t cell tolerance in autoimmune diseases","volume":"13","author":"Benne","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib244","article-title":"Particle-Based therapies for antigen specific treatment of type 1 diabetes","volume":"631","author":"Lukesh","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.smim.2025.101983_bib245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212641","article-title":"Tolerogenic dendritic cells in type 1 diabetes: no longer a concept","volume":"14","author":"Giannoukakis","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib246","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad012","article-title":"Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration","volume":"3","author":"Mansilla","year":"2023","journal-title":"Immunother. Adv."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib247","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes care"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib248","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083575","article-title":"Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice","volume":"9","author":"Di Caro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2025.101983_bib249","doi-asserted-by":"crossref","first-page":"1054968","DOI":"10.3389\/fimmu.2022.1054968","article-title":"Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients","volume":"13","author":"Nikolic","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib250","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.631463","article-title":"Stem cell-based clinical trials for diabetes mellitus","volume":"12","author":"Klerk","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.smim.2025.101983_bib251","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3389\/fimmu.2019.00694","article-title":"Activated mesenchymal stromal cells process and present antigens regulating adaptive immunity","volume":"10","author":"Van Megen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib252","doi-asserted-by":"crossref","first-page":"1227133","DOI":"10.3389\/fimmu.2023.1227133","article-title":"Novel engineered b lymphocytes targeting islet-specific t cells inhibit the development of type 1 diabetes in non-obese diabetic scid mice","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib253","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-019-0213-9","article-title":"Targeting innate immune mediators in type 1 and type 2 diabetes","volume":"19","author":"Donath","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib254","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib255","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib256","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000348","article-title":"CD56dimCD16dim natural killer (NK) cells: the forgotten population","volume":"4","author":"Zimmer","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.smim.2025.101983_bib257","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib258","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.ai.2019.11.002","article-title":"Tissue-resident NK cells and other innate lymphoid cells","volume":"145","author":"Zhou","year":"2020","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib259","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.immuni.2023.11.018","article-title":"Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection","volume":"57","author":"Torcellan","year":"2024","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib260","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat. Immunol."},{"issue":"45","key":"10.1016\/j.smim.2025.101983_bib261","doi-asserted-by":"crossref","first-page":"11357","DOI":"10.1073\/pnas.1815756115","article-title":"Natural killer cells might adapt their inhibitory receptors for memory","volume":"115","author":"Cooper","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"90","key":"10.1016\/j.smim.2025.101983_bib262","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi3974","article-title":"Antigen-specific memory NK cell responses against HIV and influenza use the NKG2\/HLA-E axis","volume":"8","author":"Jost","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib263","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib264","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The natural cytotoxicity receptors in health and disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/IR:35:3:263","article-title":"The CD94\/NKG2 family of receptors: from molecules and cells to clinical relevance","volume":"35","author":"Borrego","year":"2006","journal-title":"Immunol. Res."},{"issue":"21","key":"10.1016\/j.smim.2025.101983_bib266","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1073\/pnas.0402065101","article-title":"Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity","volume":"101","author":"Poirot","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib267","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.4049\/jimmunol.0804358","article-title":"Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice","volume":"184","author":"Brauner","year":"2010","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib268","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/diab.39.7.836","article-title":"Intrinsic cytotoxicity of natural killer cells to pancreatic islets in vitro","volume":"39","author":"Akamura","year":"1990","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib269","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08916939908993854","article-title":"Diabetes prone BB rats are severely deficient in natural killer t cells","volume":"31","author":"Iwakoshi","year":"1999","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib270","first-page":"171","article-title":"The suppressive effect of anti-asialo GM1 antibody on low-dose streptozotocin-induced diabetes in CD-1 mice","volume":"16","author":"Maruyama","year":"1991","journal-title":"Diabetes Research (Edinburgh Scotland)"},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib271","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074033","article-title":"The expression of the beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated in type 2 diabetes","volume":"8","author":"Gur","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib272","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.4049\/jimmunol.1101269","article-title":"Recognition and killing of human and murine pancreatic \u03b2 cells by the NK receptor NKp46","volume":"187","author":"Gur","year":"2011","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib273","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ni.1834","article-title":"The activating receptor NKp46 is essential for the development of type 1 diabetes","volume":"11","author":"Gur","year":"2010","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib274","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/v13020156","article-title":"Influenza a virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30","volume":"13","author":"Luczo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2025.101983_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2024.06.011","article-title":"Virus as the cause of type 1 diabetes","author":"Dahl-J\u00f8rgensen","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib276","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni771","article-title":"Target cell defense prevents the development of diabetes after viral infection","volume":"3","author":"Flodstr\u00f6m","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib277","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fcimb.2020.00036","article-title":"NK cells regulate CD8+ t cell mediated autoimmunity","volume":"10","author":"Lang","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.smim.2025.101983_bib278","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00018-019-03168-4","article-title":"Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity","volume":"77","author":"Nekoua","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib279","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2337\/db09-1706","article-title":"Natural killer cells from children with type 1 diabetes have defects in NKG2D-dependent function and signaling","volume":"60","author":"Qin","year":"2011","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib280","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.immuni.2004.05.008","article-title":"NKG2D blockade prevents autoimmune diabetes in NOD mice","volume":"20","author":"Ogasawara","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2025.101983_bib281","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2012.08.001","article-title":"NKG2D blockade facilitates diabetes prevention by antigen-specific tregs in a virus-induced model of diabetes","volume":"40","author":"Van Belle","year":"2013","journal-title":"J. Autoimmun."},{"issue":"ement_1","key":"10.1016\/j.smim.2025.101983_bib282","article-title":"The role of NKG2D signaling in NOD diabetes is affected by the microbiota","volume":"208","author":"Markiewicz","year":"2022","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.smim.2025.101983_bib283","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.3390\/ijms242417545","article-title":"The role of NKG2D and its ligands in autoimmune diseases: new targets for immunotherapy","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib284","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.4049\/jimmunol.181.10.7073","article-title":"NKG2D-RAE-1 receptor-ligand variation does not account for the NK cell defect in nonobese diabetic mice","volume":"181","author":"Maier","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib285","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/1440-1681.12699","article-title":"Decreased percentage of NKG 2D+ NK cells in patients with incident onset of type 1 diabetes","volume":"44","author":"Zhang","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib286","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2337\/db19-0979","article-title":"NKG2D signaling within the pancreatic islets reduces NOD diabetes and increases protective central memory CD8+ T-Cell numbers","volume":"69","author":"Trembath","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib287","article-title":"Type 1 and 2 diabetes are associated with reduced natural killer cell cytotoxicity","volume":"379","author":"Kim","year":"2022","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib288","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.722979","article-title":"Natural killer cells as key mediators in type I diabetes immunopathology","volume":"12","author":"Gardner","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib289","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2567.2010.03360.x","article-title":"Natural killer cells in human autoimmune diseases","volume":"131","author":"Schleinitz","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.smim.2025.101983_bib290","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2016.00251","article-title":"Recognition and regulation of t cells by NK cells","volume":"7","author":"Pallmer","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib291","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645850","article-title":"The effect of unconventional cytokine combinations on NK-cell responses to viral infection","volume":"12","author":"Ochayon","year":"2021","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.smim.2025.101983_bib292","first-page":"4441","article-title":"IL-5 promotes induction of antigen-specific CD4+ CD25+ t regulatory cells that suppress autoimmunity","volume":"119","author":"Tran","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib293","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biom12010004","article-title":"Role of IL-10-producing natural killer cells in the regulatory mechanisms of inflammation during systemic infection","volume":"12","author":"Martinez-Espinosa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.smim.2025.101983_bib294","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611522","article-title":"NK cell subsets changes in partial remission and early stages of pediatric type 1 diabetes","volume":"11","author":"Gomez-Mu\u00f1oz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib295","doi-asserted-by":"crossref","first-page":"1403752","DOI":"10.3389\/fimmu.2024.1403752","article-title":"Beta cells deficient for renalase counteract autoimmunity by shaping natural killer cell activity","volume":"15","author":"Bode","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib296","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189615","article-title":"Identification of GAD65 AA 114-122 reactive'memory-like'NK cells in newly diagnosed type 1 diabetic patients by HLA-class I pentamers","volume":"12","author":"Perri","year":"2017","journal-title":"Plos One"},{"key":"10.1016\/j.smim.2025.101983_bib297","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1007\/s00125-011-2299-x","article-title":"An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes","volume":"54","author":"Mehers","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib298","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/db06-0493","article-title":"Altered natural killer cells in type 1 diabetic patients","volume":"56","author":"Rodacki","year":"2007","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib299","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2337\/diabetes.52.10.2639","article-title":"KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects","volume":"52","author":"van der Slik","year":"2003","journal-title":"Diabetes"},{"issue":"52","key":"10.1016\/j.smim.2025.101983_bib300","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009439","article-title":"Association between KIR gene polymorphisms and type 1 diabetes mellitus (T1DM) susceptibility: a PRISMA-compliant meta-analysis","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.smim.2025.101983_bib301","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40200-020-00569-2","article-title":"Association of KIR gene polymorphisms with type 1 diabetes: a meta-analysis","volume":"19","author":"Soltani","year":"2020","journal-title":"J. Diabetes Metab. Disord."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib302","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1744-313X.2008.00804.x","article-title":"Combination of KIR 2DL2 and HLA-C1 (Asn80) confers susceptibility to type 1 diabetes in Latvians","volume":"35","author":"Shastry","year":"2008","journal-title":"Int. J. Immunogenet."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib303","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1196\/annals.1375.037","article-title":"Predominance of the group a killer Ig-like receptor haplotypes in Korean patients with T1D","volume":"1079","author":"Park","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib304","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.humimm.2006.08.295","article-title":"Investigation of KIR gene frequencies in type 1 diabetes mellitus","volume":"67","author":"Middleton","year":"2006","journal-title":"Hum. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib305","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/08820139.2023.2165940","article-title":"Association of killer cell immunoglobulin-like receptors and their HLA-ligands with type 1 diabetes among south Indian population","volume":"52","author":"Gunavathy","year":"2023","journal-title":"Immunol. Investig."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib306","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diab.39.5.583","article-title":"Prevention of type I diabetes in NOD mice by adjuvant immunotherapy","volume":"39","author":"Sadelain","year":"1990","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib307","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4049\/jimmunol.172.2.937","article-title":"Regulation of autoimmune diabetes by complete Freund\u2019s adjuvant is mediated by NK cells","volume":"172","author":"Lee","year":"2004","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib308","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/eji.200737189","article-title":"Critical role for IFN-\u03b3 in natural killer cell-mediated protection from diabetes","volume":"38","author":"Lee","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib309","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/cmi.2015.102","article-title":"Trans-presentation of interleukin-15 by interleukin-15 receptor alpha is dispensable for the pathogenesis of autoimmune type 1 diabetes","volume":"14","author":"Bobbala","year":"2017","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118936","article-title":"Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes","volume":"10","author":"Yossef","year":"2015","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib311","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/eji.201847611","article-title":"Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research","volume":"49","author":"Berhani","year":"2019","journal-title":"Eur. J. Immunol."},{"issue":"13","key":"10.1016\/j.smim.2025.101983_bib312","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111423","article-title":"Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I\u2212\/\u2212 iPSCs for \u03b2 cell replacement","volume":"40","author":"Chimienti","year":"2022","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.smim.2025.101983_bib313","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bj.2015.04.001","article-title":"Regulatory role of natural killer t cells in diabetes","volume":"38","author":"Tard","year":"2015","journal-title":"Biomed. J."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib314","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40259-022-00572-4","article-title":"Current developments in the preclinical and clinical use of natural killer t cells","volume":"37","author":"Kratzmeier","year":"2023","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib315","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/eji.1830261226","article-title":"Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse","volume":"26","author":"Gombert","year":"1996","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib316","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2337\/diab.46.4.572","article-title":"Association between \u03b1\u03b2TCR+ CD4\u2212 CD8\u2212 T-cell deficiency and IDDM in NOD\/Lt mice","volume":"46","author":"Baxter","year":"1997","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib317","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1073\/pnas.121169698","article-title":"Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse","volume":"98","author":"Shi","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib318","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.187.7.1047","article-title":"\u03b1\/\u03b2\u2013T cell receptor (TCR)+ CD4\u2212 CD8\u2212(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)\/Lt mice by the influence of interleukin (IL)-4 and\/or IL-10, jour","volume":"187","author":"Hammond","year":"1998","journal-title":"Nal. Exp. Med."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib319","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/eji.201343910","article-title":"Plasmacytoid dendritic cells license regulatory t cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes","volume":"44","author":"Beaudoin","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib320","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/eji.201141751","article-title":"NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes","volume":"41","author":"Simoni","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2025.101983_bib321","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4049\/jimmunol.2000148","article-title":"CD70 inversely regulates regulatory t cells and invariant NKT cells and modulates type 1 diabetes in NOD mice","volume":"205","author":"Ye","year":"2020","journal-title":"J. Immunol."},{"issue":"6731","key":"10.1016\/j.smim.2025.101983_bib322","doi-asserted-by":"crossref","DOI":"10.1038\/20007","article-title":"Erratum: extreme Th1 bias of invariant V\u03b124J\u03b1Q t cells in type 1 diabetes","volume":"399","author":"Wilson","year":"1999","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib323","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1189\/jlb.1106654","article-title":"Reduced CD4+ subset and Th1 bias of the human iNKT cells in type 1 diabetes mellitus","volume":"81","author":"Kis","year":"2007","journal-title":"J. Leucoc. Biol."},{"key":"10.1016\/j.smim.2025.101983_bib324","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114250","article-title":"New insights into MAIT cells in autoimmune diseases","volume":"159","author":"Fan","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib325","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ni.3854","article-title":"Cytotoxic and regulatory roles of mucosal-associated invariant t cells in type 1 diabetes","volume":"18","author":"Rouxel","year":"2017","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib326","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftw111","article-title":"Cytokines IL-17 and IL-22 in the host response to infection","volume":"74","author":"Valeri","year":"2016","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.smim.2025.101983_bib327","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1007\/s00125-021-05527-y","article-title":"MAIT cell alterations in adults with recent-onset and long-term type 1 diabetes","volume":"64","author":"Nel","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.smim.2025.101983_bib328","first-page":"1","article-title":"Interactions between islets and regulatory immune cells in health and type 1 diabetes","author":"Budd","year":"2021","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib329","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202149435","article-title":"ILC1: development, maturation, and transcriptional regulation","volume":"53","author":"Taggenbrock","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib330","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.immuni.2017.10.015","article-title":"Interleukin-33-activated islet-resident innate lymphoid cells promote insulin secretion through myeloid cell retinoic acid production","volume":"47","author":"Dalmas","year":"2017","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib331","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cmet.2018.06.012","article-title":"Gut microbiota-stimulated innate lymphoid cells support \u03b2-defensin 14 expression in pancreatic endocrine cells, preventing autoimmune diabetes","volume":"28","author":"Miani","year":"2018","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib332","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012305","article-title":"IL-10 producing type 2 innate lymphoid cells prolong islet allograft survival","volume":"12","author":"Huang","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.smim.2025.101983_bib333","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653560","article-title":"Modulation of intestinal ILC3 for the treatment of type 1 diabetes","volume":"12","author":"Stojanovi\u0107","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2025.101983_bib334","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.3390\/molecules28083366","article-title":"Development of type 1 diabetes in mice is associated with a decrease in IL-2-producing ILC3 and foxP3+ treg in the small intestine","volume":"28","author":"Saksida","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.smim.2025.101983_bib335","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3389\/fimmu.2016.00679","article-title":"Intestinal epithelial cell regulation of adaptive immune dysfunction in human type 1 diabetes","volume":"7","author":"Graves","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib336","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s12276-023-01022-z","article-title":"Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation","volume":"55","author":"Ryu","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.smim.2025.101983_bib337","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc22-0908","article-title":"Two-year follow-up from the T1GER study: continued off-therapy metabolic improvements in children and young adults with new-onset T1D treated with golimumab and characterization of responders","volume":"46","author":"Rigby","year":"2023","journal-title":"Diabetes Care"},{"issue":"9881","key":"10.1016\/j.smim.2025.101983_bib338","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.smim.2025.101983_bib339","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150074","article-title":"IL-6 receptor blockade does not slow \u03b2 cell loss in new-onset type 1 diabetes","volume":"6","author":"Greenbaum","year":"2021","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib340","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/dom.14770","article-title":"Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled trial","volume":"24","author":"Piemonti","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib341","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib342","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2941","article-title":"TNF, TNF inducers, and TNFR2 agonists: a new path to type 1 diabetes treatment","volume":"34","author":"Faustman","year":"2018","journal-title":"Diabetes\/Metab. Res. Rev."},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib343","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs \u03b2-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2025.101983_bib344","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.591083","article-title":"Chemokines as drivers of the autoimmune destruction in type 1 diabetes: opportunity for therapeutic intervention in consideration of an optimal treatment schedule","volume":"11","author":"Christen","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"12","key":"10.1016\/j.smim.2025.101983_bib345","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.2337\/dbi15-0019","article-title":"Back from the brink: the uses of targeting the CXCL10: CXCR3 axis in type 1 diabetes","volume":"64","author":"Homann","year":"2015","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.smim.2025.101983_bib346","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bcp.15914","article-title":"Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: results from the first-in-human study in healthy adults","volume":"90","author":"Boof","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.smim.2025.101983_bib347","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102553","article-title":"The intestinal microbiome in type 1 diabetes: bridging early childhood exposures with translational advances","volume":"94","author":"Guvenc","year":"2025","journal-title":"Curr. Opin. Immunol."},{"issue":"7728","key":"10.1016\/j.smim.2025.101983_bib348","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-018-0620-2","article-title":"The human gut microbiome in early-onset type 1 diabetes from the TEDDY study","volume":"562","author":"Vatanen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.101983_bib349","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123187","article-title":"Gut microbiota as a modulator of type 1 diabetes: a molecular perspective","volume":"359","author":"Nikola","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.smim.2025.101983_bib350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974178","article-title":"Host-microbiota interactions shaping T-cell response and tolerance in type 1 diabetes","volume":"13","author":"Majumdar","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib351","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/imr.13345","article-title":"Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?","volume":"325","author":"Fuhri Snethlage","year":"2024","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.smim.2025.101983_bib352","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ni.3713","article-title":"Gut microbial metabolites limit the frequency of autoimmune t cells and protect against type 1 diabetes","volume":"18","author":"Mari\u00f1o","year":"2017","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib353","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40200-022-01006-2","article-title":"Evidence and possible mechanisms of probiotics in the management of type 1 diabetes mellitus","volume":"21","author":"Dovi","year":"2022","journal-title":"J. Diabetes Metab. Disord."},{"issue":"719","key":"10.1016\/j.smim.2025.101983_bib354","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0353","article-title":"Immune responses to gut bacteria associated with time to diagnosis and clinical response to t cell\u2013directed therapy for type 1 diabetes prevention","volume":"15","author":"Xie","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2025.101983_bib355","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3389\/fimmu.2017.01961","article-title":"Lactococcus lactis as a versatile vehicle for tolerogenic immunotherapy","volume":"8","author":"Cook","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib356","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00125-019-4811-7","article-title":"Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes","volume":"62","author":"Dunne","year":"2019","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib357","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/vaccines13010050","article-title":"Rotavirus vaccination protects against diabetes mellitus type 1 in children in developed countries: a systematic review and Meta-Analysis","volume":"13","author":"Kosmeri","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.smim.2025.101983_bib358","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s43856-023-00357-y","article-title":"Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review","volume":"3","author":"Felton","year":"2023","journal-title":"Commun. Med."},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib359","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00125-023-06076-2","article-title":"Genetic engineering of regulatory t cells for treatment of autoimmune disorders including type 1 diabetes","volume":"67","author":"Tuomela","year":"2024","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.smim.2025.101983_bib360","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41574-023-00853-0","article-title":"Heterogeneity and endotypes in type 1 diabetes mellitus","volume":"19","author":"Redondo","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"11","key":"10.1016\/j.smim.2025.101983_bib361","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.smim.2025.101983_bib362","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.962177","article-title":"Synergistic targeting of immunologic pathways to empower durable tolerance therapies","volume":"13","author":"Nepom","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101983_bib363","series-title":"Methods and Protocols","first-page":"69","article-title":"Rat models of human type 1 diabetes","author":"Lenzen","year":"2020"},{"issue":"4","key":"10.1016\/j.smim.2025.101983_bib364","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.78","article-title":"Streptozotocin-induced diabetic models in mice and rats","volume":"1","author":"Furman","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.smim.2025.101983_bib365","series-title":"Methods and Protocols","first-page":"93","article-title":"Mouse models of virus-induced type 1 diabetes","author":"Christoffersson","year":"2020"},{"issue":"10","key":"10.1016\/j.smim.2025.101983_bib366","doi-asserted-by":"crossref","first-page":"a041587","DOI":"10.1101\/cshperspect.a041587","article-title":"Advancing animal models of human type 1 diabetes","volume":"14","author":"Serreze","year":"2024","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.smim.2025.101983_bib367","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101417","article-title":"Modeling human T1D-associated autoimmune processes","volume":"56","author":"Khosravi-Maharlooei","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.smim.2025.101983_bib368","doi-asserted-by":"crossref","DOI":"10.1111\/jpc.70016","article-title":"The current landscape for screening and monitoring of Early-Stage type 1 diabetes","author":"Narayan","year":"2025","journal-title":"J. Paediatr. Child Health"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:48:20Z","timestamp":1772880500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":368,"alternative-id":["S1044532325000557"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.101983","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune diabetes and targets for immunomodulation","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.101983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101983"}}